The CHEK2 kinase (Chk2 in mouse) is a member of a DNA damage response pathway that regulates cell cycle arrest at cell cycle checkpoints and facilitates the repair of dsDNA breaks by a recombination-mediated mechanism. There are numerous variants of the CHEK2 gene, at least one of which, CHEK2*1100delC (SNP), associates with breast cancer. A mouse model in which the wild-type Chk2 has been replaced by a Chk2*1100delC allele was tested for elevated risk of spontaneous cancer and increased sensitivity to challenge by a carcinogenic compound. Mice homozygous for Chk2*1100delC produced more tumors than wild-type mice, whereas heterozygous mice were not statistically different. When fractionated by gender, however, homozygous and heterozygous mice developed spontaneous tumors more rapidly and to a far greater extent than wild-type mice, indicative of a marked gender bias in mice harboring the variant allele. Consistent with our previous data showing elevated genomic instability in mouse embryonic fibroblasts (MEFs) derived from mice homozygous for Chk2*1100delC, the level of Cdc25A was elevated in heterozygous and homozygous MEFs and tumors. When challenged with the carcinogen 7,12-dimethylbenz[a]anthracene, all mice, regardless of genotype, had a reduced lifespan. Latency for mammary tumorigenesis was reduced significantly in mice homozygous for Chk2*1100delC but unexpectedly increased for the development of lymphomas. An implication from this study is that individuals who harbor the variant CHEK2*1100delC allele not only are at an elevated risk for the development of cancer but also that this risk can be further increased as a result of environmental exposure.
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cancer predisposition ͉ Cdc25A ͉ polymorphism F amilial early-onset breast cancer is attributable in large part to variant germ-line alleles of BRCA1 and BRCA2 (1) . A substantial fraction of breast cancers with a familial component that affect young women with wild-type BRCA1 and BRCA2 may be explained by genes with low-or moderate-penetrance alleles (2) , prompting a continued search for allelic variants that are associated with an elevated risk for breast cancer (3, 4) . A specific variant of CHEK2 (cell cycle checkpoint kinase 2), designated CHEK2*1100delC, in which a C is deleted at nucleotide position 1100 (i.e., 1100delC), was identified first in a Li-Fraumeni family with wild-type p53 (5) . Although an association of CHEK2*1100delC with Li-Fraumeni syndrome was suggested initially (5), such an association has been questioned subsequently (6) . Heterozygosity at CHEK2*1100delC, however, does contribute to breast cancer susceptibility in European and North American populations (7-13) and produces a 3-fold increase in the risk of breast cancer in women within the general population (7) . A meta-analysis of 26,000 cases and 27,000 controls further confirmed that the CHEK2*1100delC allele confers a 3-to 5-fold increase in risk for breast cancer (13) . With fixed-effect models for CHEK2*1100delC heterozygotes versus noncarriers, the aggregated odds ratios were 2.7 for unselected breast cancer, 2.6 for early onset breast cancer, and 4.8 for familial breast cancer. In the last case, this odds ratio corresponds to a 37% cumulative risk of breast cancer at 70 years of age in heterozygotes, which compares with similar estimates of 57% for BRCA1 heterozygotes and 49% for BRCA2 heterozygotes (13) .
The CHEK2 protein resides predominantly in the nucleus. In response to DNA double-strand breaks, it participates in cell cycle arrest and in initiating DNA repair (14, 15) . Among its many targets, CHEK2 phosphorylates serine 20 on p53 (16) (17) (18) and serine 123 on Cdc25A (19, 20) . Phosphorylation of Cdc25A by CHEK2 contributes to its ubiquitinylation and consequent proteasome-mediated degradation (21) . Cdc25A is a bifunctional phosphatase whose targets include threonine 14 and tyrosine 15 on Cdk2, dephosphorylation of which is necessary for cells to transit from the G 1 to S phase (21) . In the absence of CHEK2 kinase activity, Cdc25A should be stabilized, and the G 1 checkpoint should be impaired, leading to a degree of genomic instability.
The single cytosine deletion at nucleotide position 1100 of CHEK2 produces a frameshift mutation. The CHEK2*1100delC-encoded protein is truncated with a nonsense amino-terminal tail and lacks kinase activity (3). Because CHEK2*1100delC mRNA is degraded by nonsense-mediated mRNA decay (NMD) (22) , the truncated protein is not detectable by Western blots (23) . However, in the Chk2*1100delC mouse model, NMD appears variable between tissues (22) . Thus, impaired CHEK2 function may lead to genomic instability and cancer by compromising the regulation of Cdc25A stability.
Women who are heterozygous for CHEK2*1100delC develop breast tumors that are positive for estrogen receptor (ER) and progesterone receptor (PR) with very high frequencies (91% and 81%, respectively) compared with noncarriers whose breast tumors are 69% ER-positive and 53% PR-positive (24) . Despite tumors being ER-positive, patients with the CHEK2*1100delC variant have a less favorable prognosis for disease-free survival and the occurrence of a contralateral tumor (24) . Males who are constitutionally heterozygous for CHEK2*1100delC are not only at a 10-fold higher risk for developing breast cancer than their noncarrier counterparts (12) but are also at an elevated risk of developing familial prostate cancer (25, 26) .
We have described previously the generation of a knockin mouse in which the wild-type CHEK2 (Chk2 in mouse) allele has been replaced with the Chk2*1100delC variant (22) . Mouse embryonic fibroblasts (MEFs) derived from mice homozygous for Chk2*1100delC have an altered cell cycle profile and show signs of genomic instability, as indicated by constitutive activation of ataxia telangiectasia mutated (ATM)-mediated signaling pathways, suggestive of persistent DNA damage. Consistent with constitutively active ATM-mediated pathways, unperturbed cells manifest an increase in frequency of DNA double-strand breaks compared with control MEFs with wild-type Chk2.
Mice in which Chk2 has been knocked out are reported not to develop spontaneous tumors (27, 28) . Topical application of 7,12-dimethylbenz[a]anthracene (DMBA), however, accelerates the formation of skin tumors (29) . In contrast, mice transgenic for a kinase-dead, dominant-negative Chk2 under control of a mouse mammary tumor virus (MMTV) promoter developed mammary tumors but only after a latency period of Ϸ20 months (30) .
We now show that Chk2*1100delC mice develop spontaneous mammary tumors and other tumor types with a shorter latency and a higher frequency than wild-type mice. Furthermore, there is a gender bias in cancer predisposition, because the overwhelming majority of mice with cancer are female. We also show that the time of tumor onset is much reduced after oral administration of DMBA. Because CHEK2*1100delC is an allele that enhances susceptibility to breast cancer and probably other tumor types in some human populations, this mouse model will help resolve whether individuals with such susceptibility alleles in the DNA damage response pathway are more susceptible to cancer and other diseases than the general population as a consequence of environmental exposure.
Results

Spontaneous Tumors Are More Prevalent in Mice Harboring the
Chk2*1100delC Allele Than in Mice with Wild-Type Chk2. MEFs derived from mice that are homozygous for Chk2*1100delC display characteristics of genomic instability (22) . The cells spontaneously accumulate in the G 2 /M and S phases, indicating that one or more DNA damage checkpoints are constitutively active. Consistent with this observation, these MEFs display nuclear ␥-H2AX foci, suggesting the presence of persistent dsDNA breaks. The ␥-H2AX foci in these cells are as numerous and as intensely stained as those in nuclei of irradiated wild-type cells. These data suggest that cells derived from mice homozygous for Chk2*1100delC are inherently genetically unstable and perhaps predispose the mice to cancer.
To test whether Chk2*1100delC mice develop spontaneous mammary tumors or other tumor types, mice heterozygous and homozygous for Chk2*1100delC and their wild-type counterparts were maintained for up to 2 years and checked every other day for tumors. Around the 11th month (46 weeks) of age, both homozygous mutant and heterozygous mice started developing tumors (Fig. 1A ) that affected several different tissues (Table 1) . When analyzed together, fewer wild-type mice developed spon- The numbers in parentheses indicate the percentage of tumors of a given tumor type based on the total number of tumors in that genotype. N represents the total number of animals in each group. taneous tumors than mice homozygous or heterozygous for Chk2*1100delC, suggesting that the presence of this allele elevated the risk for cancer. The difference in tumor formation as a function of age between homozygous mutant and wild-type mice is statistically significant (P ϭ 0.025). The difference between heterozygous and wild-type mice is not statistically significant (P ϭ 0.127) but shows a developing trend by 24 months. On the basis of pathology, the primary tumors were of multiple types and widely distributed ( Table 1) . Many of the tissues that produced spontaneous tumors are hormonally responsive and express ER (ER␣ or ER␤). Prominent among these is lung, which produces a greater proportion of spontaneous tumors in mice with Chk2*1100delC than wild-type mice. Some of the tumors were metastatic and invaded other organs, demonstrating their potentially aggressive nature.
Gender Bias in CHEK2*1100delC Predisposition to Cancer. Although differences in tumor burden as a function of age between homozygous and wild-type mice are statistically significant but less so between heterozygotes and wild-type mice, there were marked differences when the mice were fractionated by sex. In females, the differences in tumorigenesis between each of the genotypes were striking ( Fig. 1 B and D) . Furthermore, a sizable majority of mice that carried the Chk2*1100delC allele and that developed tumors were female (Fig. 1C) . These gender biases were particularly apparent in comparisons between homozygous females and males (P ϭ 0.001) but less obvious in comparisons between heterozygous females and males (P ϭ 0.11) and absent in wild-type mice (P ϭ 0.67). When compared exclusively at the 24-month end point, a larger number of heterozygous female mice had more tumors than wild-type female mice, and homozygous females had even a greater number (Fig. 1D) . In contrast, the male mice homozygous for Chk2*1100delC had significantly fewer tumors than wild-type males. That females carrying the Chk2*1100delC allele are more prone to developing tumors suggests that spontaneous tumorigenesis in these mice is partly hormone dependent, an observation that is consistent with human epidemiological data. Approx imately 90% of CHEK2*1100delC-related cancers are ER-positive (24), suggesting that hormones may contribute to CHEK2*1100delC-related human cancers.
Administration of DMBA to Chk2*1100delC Mutant Mice Reduces Latency for Mammary Tumorigenesis but Not Lymphoma Development Compared with Treated Wild-Type Mice. Although epidemiology has shown that the CHEK2*1100delC allele predisposes to breast cancer (13) , whether individuals harboring this allele are also more susceptible to cancer after exposure to a carcinogen is not known. The possibility of elevated cancer risk after exposure was tested in the Chk2*1100delC mouse model by administering DMBA orally, by gavage, to female mice of each genotype. DMBA is a known carcinogen that induces predominantly mammary tumors in rodents and other tumor types (31).
To assess whether or not the presence of Chk2*1100delC elevates risk for tumor formation after carcinogenic challenge, female mice of all three genotypes were treated with DMBA and monitored for the development of tumors. Exposure to DMBA resulted in significantly decreased tumor latency and accelerated death in each of the three groups of mice compared with mice that were not exposed (compare time frames in Figs. 1 and 2A) . By 40 weeks of age, 80-90% of the treated mice of all three genotypes were dead (Fig.  2 A) . When fractionated by cause of death (Fig. 2B ), mice that were homozygous but not heterozygous for Chk2*1100delC had a significantly reduced latency for mammary tumor onset (P ϭ 0.02 and 0.81, respectively), and increased frequency of mammary tumors compared with treated wild-type mice. Surprisingly, mice homozygous for wild-type Chk2 had a significantly higher frequency of lymphomas (Fig. 2C ) than either mice heterozygous or homozygous for the Chk2*1100delC allele (P ϭ 0.5 and 0.2, respectively), which probably accounts, in part, for the absence of a difference in the overall survival of the three genotypes after exposure to DMBA (Fig. 2 A) . The distribution of tumor types is different in female wild-type mice and female mice that are heterozygous and homozygous for Chk2*1100delC. The distribution is yet again different for those mice challenged with DMBA (Table 1) . Again, the tumors were metastatic and invaded other organs. Histopathology of some representative examples is shown in Fig. 3 .
Loss of Chk2 Function in Chk2*1100delC Mice Correlates with an
Increase in Cdc25A Protein. The mechanism by which the Chk2*1100delC confers an elevated cancer risk is not known. One of the targets of Chk2 kinase activity is the Cdc25A bifunctional phosphatase that plays a critical role in malignant human cancers and is overexpressed in a majority of solid tumors, including breast tumors (19) . Furthermore, MMTVtargeted transgenic expression of Cdc25A results in alveolar hyperplasia in mammary glands, suggesting that increased expression of Cdc25A accelerates developmental proliferation of mammary epithelial cells (32) . After DNA damage in normal cells, the cell cycle checkpoint machinery is activated, and CHEK1 and CHEK2 kinases target Cdc25A for degradation (Fig. 4A) , thereby decelerating the cell cycle. In the absence of CHEK2 kinase activity, as in CHEK2*1100delC cells, Cdc25A is degraded ineffectively, resulting in its accumulation (19) . Accumulated Cdc25A allows continued activation of cyclin/Cdk complexes and disrupts cell cycle regulation by compromising cell cycle checkpoints and leading to genomic instability and subsequent cancer. The available data relating to Cdc25A overexpression in cancer show an unequivocal relationship between Cdc25A levels and specific clinical and pathological features, such as higher-grade tumors and poor disease-free survival (33) (34) (35) .
To assess the status of Cdc25A in cells of CHEK2*1100delC mice, the levels of Cdc25A expression were assessed in MEFs from each of the three genotypes by Western blot. As illustrated in Fig. 4B , the levels of Cdc25A protein in the heterozygous cells are elevated compared with those in the wild-type cells and are even higher in the homozygous mutant cells. A similar qualitative observation was made when Cdc25A levels were assessed by immunohistochemistry in mammary tumors and normal mammary tissue (Fig. 4C) .
Discussion
Familial breast cancer accounts for 15-35% of all breast malignancies (1). Variant alleles of several genes are known now to significantly elevate risk for breast cancer, the most extensively studied of which include BRCA1 and BRCA2. The majority of familial breast cancers, however, are not directly attributable to mutant BRCA1 or BRCA2. Among these are ATM (36), CHEK2 (12, 15) , and Cdc25A (33) . Some pedigrees in which multiple members present with breast cancer indicate that CHEK2*1100delC is a variant allele that associates with an elevated frequency of breast cancer in such families. Furthermore, CHEK2*1100delC confers an increased risk of breast cancer even in women unselected for family history (13) . A second CHEK2 variant that appears to be overrepresented in women with breast cancer is CHEK2 I157T (5), but the risk associated with other CHEK2 variants is unclear.
The nucleotide deletion and consequent frameshift in CHEK2*1100delC result in the loss of much of the CHEK2 kinase domain. Consequently, some cellular substrates that are targets for CHEK2 kinase activity may have functions that are compromised. In some cases, kinase redundancy may compensate, as in the phosphorylation of serine 20 of p53. This residue is phosphorylated by CHEK2 by polo-like kinase 3 (Plk3) (37) . Serine 123 of Cdc25A also is phosphorylated by CHEK2, and this phosphorylation contributes to Cdc25A proteasome-mediated degradation after DNA damage in the form of DNA doublestrand breaks. This same residue also is phosphorylated by CHEK1, particularly after UV-induced DNA damage (38) . There are multiple sites on Cdc25A that can be phosphorylated by different kinases under various conditions and that may be partly responsible for its stability or instability (Fig. 4A ). Our data with MEFs from mice with different Chk2 genotypes, however, suggest that even though Cdc25A may be phosphorylated by other proteins, phosphorylation by Chk2 is in large part responsible for Cdc25A degradation (Fig. 4B) . There is an accumulation of Cdc25A in cells heterozygous for Chk2 and an even higher level in homozygous deficient cells. Immunostaining of mammary tumor tissues for Cdc25A showed a similar elevation of Cdc25A protein (Fig. 4C) . The MEFs homozygous for Chk2 kinase deficiency have a compromised cell cycle and exhibit genomic instability (22) , which is consistent with elevated Cdc25A levels and with the observation that Cdc25A is overexpressed in Ͼ50% of solid tumors (33-35) . To better understand the role of CHEK2*1100delC in cancer predisposition and malignant transformation, we have maintained mice that are homozygous and heterozygous for Chk2*1100delC and their wild-type counterparts for up to 24 months and assessed the effect of this variant allele on cancer initiation and development. Consistent with cancer predisposition in humans, mice harboring this Chk2 variant have a statistically significant increase in the rate of tumor formation and in the number of tumors after Ϸ1 year of age, confirming that this allele can elevate cancer risk.
Of particular note is that almost all of the mice that developed tumors were female, suggesting hormonal involvement in some Chk2-associated tumors. In humans, Ϸ91% of CHEK2*1100delC-dependent cancers are ER-positive compared with 69% in the general population. The potential involvement of ER in CHEK2*1100delC-dependent cancers suggests a model to provide a basis for understanding how CHEK2*1100delC and ER might cooperate to elevate cancer risk. The bifunctional phosphatase Cdc25A is a target of CHEK2 kinase (19) , which phosphorylates Cdc25A on serine 15 and contributes to its degradation after the introduction of DNA damage as dsDNA breaks (19) . Because CHEK2*1100delC lacks kinase activity, it cannot phosphorylate Cdc25A in response to DNA damage, thereby impairing its proteasome-mediated degradation and increasing its steady-state level. Similarly, 2-estradiol/ER is known to regulate the expression and stabilization of c-Myc (39), which in turn induces transcription of Cdc25A (40) . Thus, these two pathways may act in concert to increase Cdc25A levels to a threshold at which Cdc25A promotes genomic instability and tumorigenesis. Elevated Cdc25A, which is common to almost half of all solid tumors, promotes dephosphorylation of Cyclin E/CDK 2 and 4 complexes, which facilitates deregulated passage of cells from the G 1 to S phase and consequent genomic instability (31, 41) . Consistent with this model, the level of Cdc25A protein in the CHEK2*1100delC cells and tissues was considerably higher compared with that in wild-type cells (Fig.  4 B and C) . The model is depicted schematically in Fig. 5 . An alternative scheme might involve physical interaction between ER and one of the proteins that Chk2 regulates directly or indirectly. The androgen receptor (AR) physically binds and immunoprecipitates with BRCA2. The BRCA2 protein is phosphorylated by CHEK2 kinase to regulate its association with Rad51 (42) . A direct interaction between ER and BRCA2 has not been reported, but given the association between AR and BRCA2, such an interaction is not unlikely. If truncation of CHEK2 or loss of its kinase activity affects its putative interaction with ER and also its ability to phosphorylate BRCA2, then genomic stability may be disrupted.
The distribution of tumor types appeared to vary between female mice with different genotypes (Table 1) . Most of the tissues affected, however, are hormonally responsive. Lung appeared to be most affected and mammary tumors less so. That lung tumors were among the most common tumor types in mice with the Chk2*1100delC allele is consistent with the observation that local estrogen levels and ER status may be important in controlling the behavior of some lung tumors and that the ER may be useful as a therapeutic target (43) (44) (45) or as a predictor of disease outcome (46) . After treatment with DMBA, mammary tumors and lung tumors were the most increased tumor types. Mammary tumors showed a clear increase in numbers and rate of onset after challenge. In contrast, the number of lymphomas that developed after challenge appeared to be suppressed. Although suppression of lymphomas may be a real phenomenon, the mice more likely die of other tumor types or for different reasons before the lymphomas manifest.
The data indicate that mouse Chk2*1100delC, like its human counterpart, is a low-penetrance allele that recapitulates the human cancer phenotype. The data also suggest that this allele may confer an added cancer risk after environmental exposure. The very strong gender bias observed with the Chk2*1100delC mouse model predicts an association with the estrogen/ER axis and, if correct, affords a rationale for therapeutic targets.
Materials and Methods
Derivation of MEFs and Western Blot. The Chk2*1100delC mice and MEFs were generated as described (22) . Western blots for Cdc25A were performed by using a commercially available polyclonal antibody (sc-97; Santa Cruz Biotechnology).
DMBA Treatment. The Chk2*1100delC mice were backcrossed with FVB mice for at least five generations. Four-week-old Chk2*1100delC female mice, either homozygous or heterozygous for the allele, together with their wildtype control littermates, were treated by gavage with 100 g of DMBA (Sigma) dissolved in 0.1 mL of sunflower oil three times per week for 6 subsequent weeks. Control female animals only received the solvent during the treatment period. All mice were weighed weekly and checked for the development of tumors until the age of 43 weeks (39 weeks after start of the treatment).
Moribund animals or those with visible tumors were killed as were surviving mice at the end of the experiment. Tumors and tissues were collected, processed for histopathology, and preserved in 10% neutral buffered formalin (catalog no. 9400 -5; Richard-Allan Scientific). The tissues were embedded in paraffin wax, sectioned at 5 m, and stained with hematoxylin and eosin for histopathologic evaluation.
Tissue Collection and Analyses. Mice were killed, and tissues were dissected, mounted on glass slides, and fixed and stained in carmine alum solution as described for whole-mount analysis (47) . For immunohistochemical analysis, tissues were fixed as above, processed, and embedded in paraffin. Cdc25A staining was done with the same antibody as above.
Statistical Analysis. Comparisons of survival, time of tumor onset, and frequencies of tumors between cohorts of mice for the three genotypes were performed by using the Cox-Mantel log-rank test to evaluate levels of significance at a 95% confidence interval. Differences were determined to be statistically significant when P Ͻ 0.05, unless otherwise noted.
